Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Metabolic engineering of microbial competitive advantage for industrial fermentation processes.

Shaw AJ, Lam FH, Hamilton M, Consiglio A, MacEwen K, Brevnova EE, Greenhagen E, LaTouf WG, South CR, van Dijken H, Stephanopoulos G.

Science. 2016 Aug 5;353(6299):583-6. doi: 10.1126/science.aaf6159.

2.

H7N9 Live Attenuated Influenza Vaccine Is Highly Immunogenic, Prevents Virus Replication, and Protects Against Severe Bronchopneumonia in Ferrets.

de Jonge J, Isakova-Sivak I, van Dijken H, Spijkers S, Mouthaan J, de Jong R, Smolonogina T, Roholl P, Rudenko L.

Mol Ther. 2016 May;24(5):991-1002. doi: 10.1038/mt.2016.23. Epub 2016 Jan 22.

3.

Synthetic Long Peptide Influenza Vaccine Containing Conserved T and B Cell Epitopes Reduces Viral Load in Lungs of Mice and Ferrets.

Rosendahl Huber SK, Camps MG, Jacobi RH, Mouthaan J, van Dijken H, van Beek J, Ossendorp F, de Jonge J.

PLoS One. 2015 Jun 5;10(6):e0127969. doi: 10.1371/journal.pone.0127969. eCollection 2015.

4.

Differential B-cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine.

van Westen E, Wijmenga-Monsuur AJ, van Dijken HH, van Gaans-van den Brink JA, Kuipers B, Knol MJ, Berbers GA, Sanders EA, Rots NY, van Els CA.

Clin Infect Dis. 2015 Aug 1;61(3):342-9. doi: 10.1093/cid/civ274. Epub 2015 Apr 1.

5.

Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.

Isakova-Sivak I, de Jonge J, Smolonogina T, Rekstin A, van Amerongen G, van Dijken H, Mouthaan J, Roholl P, Kuznetsova V, Doroshenko E, Tsvetnitsky V, Rudenko L.

PLoS One. 2014 Jul 24;9(7):e102339. doi: 10.1371/journal.pone.0102339. eCollection 2014.

6.

Expression of human CEACAM1 in transgenic mice limits the Opa-specific immune response against meningococcal outer membrane vesicles.

Zariri A, van Dijken H, Hamstra HJ, van der Flier M, Vidarsson G, van Putten JP, Boog CJ, van den Dobbelsteen G, van der Ley P.

Vaccine. 2013 Nov 12;31(47):5585-93. doi: 10.1016/j.vaccine.2013.07.069. Epub 2013 Aug 6.

PMID:
23933369
7.

Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease.

Kaaijk P, van Straaten I, van de Waterbeemd B, Boot EP, Levels LM, van Dijken HH, van den Dobbelsteen GP.

Vaccine. 2013 Feb 4;31(7):1065-71. doi: 10.1016/j.vaccine.2012.12.031. Epub 2012 Dec 27.

PMID:
23273968
8.

Differential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis.

Fransen F, Stenger RM, Poelen MC, van Dijken HH, Kuipers B, Boog CJ, van Putten JP, van Els CA, van der Ley P.

PLoS One. 2010 Dec 23;5(12):e15692. doi: 10.1371/journal.pone.0015692.

9.

Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.

van de Waterbeemd B, Streefland M, van der Ley P, Zomer B, van Dijken H, Martens D, Wijffels R, van der Pol L.

Vaccine. 2010 Jul 5;28(30):4810-6. doi: 10.1016/j.vaccine.2010.04.082. Epub 2010 May 16.

PMID:
20483197
10.

Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity.

Arenas J, van Dijken H, Kuipers B, Hamstra HJ, Tommassen J, van der Ley P.

Clin Vaccine Immunol. 2010 Apr;17(4):487-95. doi: 10.1128/CVI.00423-09. Epub 2010 Jan 27.

11.

Hyperproliferation of B cells specific for a weakly immunogenic PorA in a meningococcal vaccine model.

Luijkx TA, van Gaans-van den Brink JA, van Dijken HH, van den Dobbelsteen GP, van Els CA.

Clin Vaccine Immunol. 2008 Oct;15(10):1598-605. doi: 10.1128/CVI.00192-08. Epub 2008 Sep 3.

12.

Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs.

van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L.

Vaccine. 2007 Mar 22;25(13):2491-6. Epub 2006 Sep 20.

PMID:
17023098
13.

Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine.

Luijkx T, van Dijken H, van Els C, van den Dobbelsteen G.

Vaccine. 2006 Mar 6;24(10):1569-77. Epub 2005 Oct 24.

PMID:
16298029
14.

Porin A-specific antibody avidity in patients who are convalescing from meningococcal B disease.

Vermont CL, van Dijken HH, de Groot R, van den Dobbelsteen GP.

Pediatr Res. 2005 Jul;58(1):149-52. Epub 2005 Mar 17.

PMID:
15774845
15.

PorA-specific differences in antibody avidity after vaccination with a hexavalent Men B outer membrane vesicle vaccine in toddlers and school children.

Vermont CL, Van Dijken HH, De Groot R, Van Alphen L, Van Den Dobbelsteen GP.

Vaccine. 2004 Aug 13;22(23-24):3008-13.

PMID:
15297049
16.

Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form.

Luijkx TA, van Dijken H, Hamstra HJ, Kuipers B, van der Ley P, van Alphen L, van den Dobbelsteen G.

Infect Immun. 2003 Nov;71(11):6367-71.

17.

Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.

Wedege E, Kuipers B, Bolstad K, van Dijken H, Frøholm LO, Vermont C, Caugant DA, van den Dobbelsteen G.

Infect Immun. 2003 Jul;71(7):3775-81.

18.

Functional activity of antibodies against the recombinant OpaJ protein from Neisseria meningitidis.

de Jonge MI, Vidarsson G, van Dijken HH, Hoogerhout P, van Alphen L, Dankert J, van der Ley P.

Infect Immun. 2003 May;71(5):2331-40.

20.

Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.

Vermont CL, van Dijken HH, Kuipers AJ, van Limpt CJ, Keijzers WC, van der Ende A, de Groot R, van Alphen L, van den Dobbelsteen GP.

Infect Immun. 2003 Apr;71(4):1650-5.

21.

Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.

Vermont CL, van Dijken HH, van Limpt CJ, de Groot R, van Alphen L, van Den Dobbelsteen GP.

Infect Immun. 2002 Feb;70(2):584-90.

22.

Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine.

de Kleijn E, van Eijndhoven L, Vermont C, Kuipers B, van Dijken H, Rümke H, de Groot R, van Alphen L, van den Dobbelsteen G.

Vaccine. 2001 Nov 12;20(3-4):352-8.

PMID:
11672897
23.

Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age.

de Kleijn ED, de Groot R, Labadie J, Lafeber AB, van den Dobbelsteen G, van Alphen L, van Dijken H, Kuipers B, van Omme GW, Wala M, Juttmann R, Rümke HC.

Vaccine. 2000 Feb 14;18(15):1456-66.

PMID:
10618543
24.

A new rat model of otitis media caused by Streptococcus pneumoniae: conditions and application in immunization protocols.

van der Ven LT, van den Dobbelsteen GP, Nagarajah B, van Dijken H, Dortant PM, Vos JG, Roholl PJ.

Infect Immun. 1999 Nov;67(11):6098-103.

25.

Light microscopic and ultrastructural investigation of the dopaminergic innervation of the ventrolateral outgrowth of the rat inferior olive.

Toonen M, van Dijken H, Holstege JC, Ruigrok TJ, Koekkoek SK, Hawkins RK, Teune TM, vd Burg J, De Zeeuw CI.

Brain Res. 1998 Aug 17;802(1-2):267-73.

PMID:
9748623
26.

Human B- and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine.

van der Voort ER, van Dijken H, Kuipers B, van der Biezen J, van der Ley P, Meylis J, Claassen I, Poolman J.

Infect Immun. 1997 Dec;65(12):5184-90.

27.

Distribution of dopamine immunoreactivity in the rat, cat and monkey spinal cord.

Holstege JC, Van Dijken H, Buijs RM, Goedknegt H, Gosens T, Bongers CM.

J Comp Neurol. 1996 Dec 23;376(4):631-52.

PMID:
8978475
28.

Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.

van der Voort ER, van der Ley P, van der Biezen J, George S, Tunnela O, van Dijken H, Kuipers B, Poolman J.

Infect Immun. 1996 Jul;64(7):2745-51.

29.

Ultrastructural localization of cholinergic muscarinic receptors in rat brain cortical capillaries.

Luiten PG, de Jong GI, Van der Zee EA, van Dijken H.

Brain Res. 1996 May 13;720(1-2):225-9.

PMID:
8782916
30.

Localization of dopamine D2 receptor in rat spinal cord identified with immunocytochemistry and in situ hybridization.

van Dijken H, Dijk J, Voom P, Holstege JC.

Eur J Neurosci. 1996 Mar;8(3):621-8.

PMID:
8963454
31.

Short inescapable stress produces long-lasting changes in the brain-pituitary-adrenal axis of adult male rats.

van Dijken HH, de Goeij DC, Sutanto W, Mos J, de Kloet ER, Tilders FJ.

Neuroendocrinology. 1993 Jul;58(1):57-64.

PMID:
8264856
32.

Characterization of stress-induced long-term behavioural changes in rats: evidence in favor of anxiety.

van Dijken HH, Mos J, van der Heyden JA, Tilders FJ.

Physiol Behav. 1992 Nov;52(5):945-51.

PMID:
1484851
33.

Corticosteroid receptor plasticity in the central nervous system of various rat models.

Sutanto W, Oitzl MS, Rots NY, Schöbitz B, Van den Berg DT, Van Dijken HH, Mos J, Cools AR, Tilders FJ, Koolhaas JM, et al.

Endocr Regul. 1992 Sep;26(3):111-8.

PMID:
1339189
34.

Localization of dopamine D2 receptor mRNA with non-radioactive in situ hybridization histochemistry.

Brouwer N, Van Dijken H, Ruiters MH, Van Willigen JD, Ter Horst GJ.

Neurosci Lett. 1992 Aug 17;142(2):223-7.

PMID:
1454220
35.

Inescapable footshocks induce progressive and long-lasting behavioural changes in male rats.

Van Dijken HH, Van der Heyden JA, Mos J, Tilders FJ.

Physiol Behav. 1992 Apr;51(4):787-94.

PMID:
1594677
36.

Effects of anxiolytic and antidepressant drugs on long-lasting behavioural deficits resulting from one short stress experience in male rats.

Van Dijken HH, Tilders FJ, Olivier B, Mos J.

Psychopharmacology (Berl). 1992;109(4):395-402.

PMID:
1365853
37.

Differential central effects of mineralocorticoid and glucocorticoid agonists and antagonists on blood pressure.

van den Berg DT, de Kloet ER, van Dijken HH, de Jong W.

Endocrinology. 1990 Jan;126(1):118-24.

PMID:
2293978
38.

Brain corticosteroid receptors and regulation of arterial blood pressure.

van den Berg DT, de Kloet ER, van Dijken HH, de Jong W.

J Hypertens Suppl. 1989 Dec;7(6):S202-3.

PMID:
2561139

Supplemental Content

Loading ...
Support Center